Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer

Yin, Shuping; Cui, Han; Qin, Shuang; Yu, Shengnan

doi:10.1016/j.biopha.2023.115355

Cited by 7 publications

(1 citation statement)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…External beam and internally delivered radiation (brachytherapy) are often used in the radiotherapy of cervical cancer [ 17 , 18 ]. Newer treatments, such as targeted therapy and immunotherapy, have been used in the last decades, including current FDA approval of the combination of pembrolizumab and chemoradiotherapy for the treatment of newly diagnosed, high-risk, locally advanced cervical cancer [ 19 , 20 , 21 , 22 , 23 , 24 ]. However, limitations of these approaches include long treatment regimens, side effects, and high costs that drive persistent disparities and impact patient’s overall quality of life [ 25 , 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment

Moreau,

Keno,

China

et al. 2024

Cancers

View full text Add to dashboard Cite

Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (* p < 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.

show abstract